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LOCAL IMMUNOSUPPRESSION (L-IMS) has beenused for many years,1 particularly in animal experi-
mental organ transplantation. It has also been used in
human kidney transplantation.2 The rationale for this prac-
tice is that the most important immunologic events leading
to rejection occur in the graft. For instance, it has been
demonstrated that local expansion of donor-specific T cells
may mediate graft rejection after the first posttransplant
days, without the participation of the circulating pool of
lymphocytes.1 Thus, it should be expected that local intraar-
terial delivery of the immunosuppressive agents reaches
higher levels of efficacy for the same doses or even for lower
doses than when they are systemically administered.
To our knowledge, despite the encouraging results of
many experimental studies, no clinical use of L-IMS has yet
been carried out in human organ transplantation, with the
exception of some data from the 1960s.
Small bowel transplantation (SBTx) still carries a high
incidence of severe cellular rejection, with serious and
devastating consequences. Faced with two particularly dif-
ficult patients, the present investigators used L-IMS for
several weeks posttransplantation, with lower doses of
immunosuppressive drugs and obvious success. These two
cases and the technique of L-IMS are reported herein.
PATIENTS AND METHODS
Patient 1
The first patient (S.A.F.S.), an 18-year-old boy, lost the fourth
portion of the duodenum, the whole small bowel, and the right
colon following a complete volvulus procedure on September 30,
1994; 10 days later he was admitted to our department for
evaluation. He had a wide duodenostomy in the upper left quad-
rant of the abdomen, and his weight was 52 kg and height 1.8 m;
routine laboratory values were normal as well as chest X-rays,
ECG, and liver and respiratory functional tests. Abdominal Dopp-
ler ultrasound and aortography showed no superior mesenteric
artery. A long-term central venous catheter was placed for total
parenteral nutrition at home (THPN). Four months later, he had
gained 18 kg. Later he experienced several catheter-related infec-
tions, which led to the replacement of the catheter. At the end of
the second year, he developed chronic cholestasis with advanced
liver fibrosis. An extremely severe episode of bacterial and fungal
sepsis prompted his admission to the ICU. During 1 month, this
situation proved to be resistant to all treatments. In spite of this, we
performed a combined liver and SBTx (LSBTx). Prothrombin time
was 5 seconds above control and total bilirubin was 36.8 mg/dL.
The donor was a young man, ABO-compatible, with no HLA
match. Procurement and transplantation were performed accord-
ing to established rules.
Immunosuppression was based on intravenous tacrolimus, 0.02
to 0.12 mg/kg per day (total bilirubin levels 12 to 40 ng/mL for the
first 2 weeks, then 12 to 20 ng/mL); methylprednisolone initially as
two “bolus” injections of 250 mg, tapered to 20 mg/d by the end of
the first month; and azathioprine as a single dose of 2 mg/kg. Oral
selective bowel decontamination, aciclovir, and cotrimoxazol were
administered according to routine protocol for our liver transplant
patients. Also given were broad-spectrum antibiotics and ampho-
tericin B for 2 weeks, and subsequently when necessary, and
prostaglandin E1 during the first week. Routine small bowel
biopsies were performed every other day for the first 2 weeks, and
thereafter whenever indicated. The hepatic graft showed good
function from the very beginning and the small bowel returned to
normal peristalsis by day 6. A small bowel biopsy performed at this
time showed acute severe cellular rejection, which responded to
boluses of steroids and increased levels of tacrolimus. By week 2,
severe interstitial pneumonia required urgent mechanical ventila-
tion. Along with intensive antibiotic therapy, immunosuppression
was substantially reduced. The patient was free from mechanical
ventilation 1 month later, while maintaining sepsis and having lost
the bowel graft due to rejection.
The grafted liver maintained good function throughout this
period, and at 2 months posttransplant the small bowel graft was
removed. At 3 months, a second SBTx was carried out from a
cadaveric ABO-identical, two-HLA-match donor. This time, a
15-cm segment of the middle colic artery (MCA) of the donor was
isolated continuously with the superior mesenteric artery (SMA)
(Fig 1). A very narrow catheter was inserted into the MCA, its tip
reaching the emergence of that artery from the SMA.
L-IMS consisted of methylprednisolone and tacrolimus via cath-
eter for 3 weeks (details in Table 1).
There were three episodes of moderate-to-severe acute rejection
that responded well to boluses of methylprednisolone and in-
creased doses of tacrolimus. By week 3 of L-IMS the catheter
occluded, and oral and intravenous IMS was started. The intraar-
terial catheter was withdrawn and the distal end of the MCA was
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ligated. At 3 months after retransplant the patient returned home
free from parenteral nutrition. At 32 months he passes four to eight
loose stools per day, his weight is stable, and he is able to work.
Patient 2
The second patient (R.P.L.G.), a 17-year-old boy, lost his small
bowel following a volvulus when he was 9 years of age; the
remaining 30 cm of proximal jejunum was anastomosed to the
colon. He was on parenteral nutrition and oral intake; catheter-
related infections and thrombosis of venous accesses were the
major complications. He had been submitted to a lengthening of
the remaining jejunum (Biancchi operation) followed by some
improvement in nutrition. However, 1 year later he developed
severe hypocalcemia that motivated several hospital admissions
and was again put on parenteral nutrition. Growth retardation was
striking and loss of venous accesses became a severe complication.
In the beginning of 1998 he was referred and admitted to our
department. He was wheelchair-bound, severely malnourished, and
had growth far below normal, with hypoalbuminemia, anemia,
hypocalcemia, generalized severe osteoporosis and osteopenia, and
some crushed vertebrae. Liver, heart, lung, and kidney functions
were normal.
He passed several stools a day that were watery and with rests of
recent meals. No venous access was available, with extensive
obliteration of both vena cava. A transthoracic venous access to the
superior vena cava was then created; highly caloric total parenteral
nutrition and physiotherapy were started. Weight gain was very
slight after 4 months, although some improvements were seen, in
particular the disappearance of muscle spasms.
In September 1998 he received a small bowel graft from a
cadaveric, ABO-identical, total HLA-mismatched donor. The ileo-
cecal valve and a small portion of the cecum were kept with the small
bowel. Procurement and transplant techniques were the same as for
the retransplant in the first patient, with the portal vein of the recipient
having been recanalized by venoplasty. L-IMS was instituted as
described for the first patient, but was maintained for 7 weeks.
Two major episodes of acute cellular rejection responded well to
the 250-mg boluses of steroids and increased levels of tacrolimus
(details in Table 2). One of these two episodes was followed by
severe sepsis and pneumonia that required mechanical ventilation
for a few days.
The patient was dismissed from the hospital 106 days after
transplantation. In spite of two to four bowel movements per day
he gained 17 kg in weight and 7 cm in height after 1 year
posttransplant. His body mass index is 18.8 kg/m2. Quite striking
was the disappearance of bone pain at 3 months and normalization
of the spine curves. At 6 months he could play tennis for 1 hour. He
is presently a happy and very successful student.
CONCLUSIONS
These two particularly difficult cases of SBTx (including an
SBTx and a retransplant) in very critical patients show that
local intraarterial immunosuppression is feasible in the
human when using cadaveric grafts. The technique devel-
oped proved to be simple and reliable. No vascular harmful
effects resulted from local intraarterial perfusion of any of
the drugs used (methylprednisolone, tacrolimus, heparin).
The total doses of IMS were lower than those usually
practiced in the routine protocol. The rejection episodes
under L-IMS were easily controlled. A variety of questions









Week 1 0.12 42 —
Week 2 0.09 38 —
Week 3 0.06 44 End of L-IMS at day 22;
acute rejection at days
18, 25, and 69
(good response to MP)
PGE1 0.04 to 0.07 ng/kg per minute (7 days).
Fig 1. The middle colic artery (MCA) was isolated and kept in
continuity with the superior mesenteric artery of the cadaveric
intestinal graft. A fine catheter was introduced into the MCA. The
distal end of the MCA was sutured to the dermal layer.







Week 1 0.08 46.2 Acute rejection (AR) at day 4
(mild)
Week 2 0.08 38.2 (local methylprednisolone)
Week 3 0.09 36
Week 4 0.05 35.5 AR at day 22 (moderate/severe)
Week 5 0.05 28.8 (local methylprednisolone)
Week 6 0.02 17.6
Week 7 0.04 12.3 Severe pneumonia (mechanical
ventilation, 7 days)
PGE1 0.04 to 0.07 ng/kg per minute (7 days).
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remain to be answered about local acute rejection effects,
pharmacodynamics, ideal doses, type of infusion (continu-
ous or boluses), etc. However, our preliminary experience
suggests that the benefits already shown in animal trials may
be realized in humans and deserve future trials.
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